Virulence capacity of different Aspergillus species from invasive pulmonary aspergillosis

The opportunistic filamentous fungus causes invasive pulmonary aspergillosis (IPA) that often turns into a fatal infection in immunocompromised hosts. However, the virulence capacity of different species and host inflammation induced by different species in IPA are not well understood. In the presen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology 2023-03, Vol.14, p.1155184-1155184
Hauptverfasser: Chen, Biao, Qian, Guocheng, Yang, Zhiya, Zhang, Ning, Jiang, Yufeng, Li, Dongmei, Li, Renzhe, Shi, Dongmei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The opportunistic filamentous fungus causes invasive pulmonary aspergillosis (IPA) that often turns into a fatal infection in immunocompromised hosts. However, the virulence capacity of different species and host inflammation induced by different species in IPA are not well understood. In the present study, host inflammation, antimicrobial susceptibilities and virulence were compared among clinical strains isolated from IPA patients. A total of 46 strains were isolated from 45 patients with the invasive infection, of which 35 patients were diagnosed as IPA. was the dominant etiological agent appearing in 25 cases (54.3%). We found that the CRP level and leukocyte counts (elevated neutrophilic granulocytes and monocytes, and reduced lymphocytes) were significantly different in IPA patients when compared with healthy individuals ( < 0.05). Antifungal susceptibilities of these Aspergillus isolates from IPA showed that 91%, 31%, 14%, and 14% were resistant to Fluconazole, Micafungin, Amphotericin B and Terbinafine, respectively. The survival rate of larvae infected by was lower than larvae infected by or ( < 0.05). was the dominant clinical etiological agent. Given the prevalence of in our local clinical settings, we may face greater challenges when treating IPA patients.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1155184